CTLA4 and acute myeloid leukemia: Although it remains unknown whether this immune checkpoint molecule plays a role in LSC resistance in AML, it is worth mentioning that CTLA4 blockade may be useful in the post-HSCT setting in hematologic malignancies, including AML [122,123].